Form D · Biotechnology
Inscripta, Inc.
Pleasanton, CA · CIK 0001667561
Offering snapshot reported Jun 1, 2023 · SEC filing
- Reported sold
- $1.86M Offering amount: $1.86M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 24, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 1, 2023 | Initial | $1,855,000 | No comparison | 2 | SEC filing |
| Jan 18, 2023 | Initial | $4,399,977 | No comparison | 4 | SEC filing |
| Jan 18, 2023 | Initial | $27,791,098 | No comparison | 5 | SEC filing |
| Apr 14, 2021 | Initial | $149,999,970 | No comparison | 32 | SEC filing |
| Nov 30, 2020 | Initial | $8,060,048 | No comparison | 1 | SEC filing |
| Nov 30, 2020 | Initial | $49,999,996 | No comparison | 6 | SEC filing |
| Dec 11, 2019 | Initial | $92,149,960 | No comparison | 12 | SEC filing |
| Apr 15, 2019 | Amendment | $49,999,979 | $24,349,997vs Jan 22, 2019 | 14 | SEC filing |
| Jan 22, 2019 | Initial | $25,649,982 | No comparison | 11 | SEC filing |
| Sep 17, 2018 | Initial | $1,146,592 | No comparison | 9 | SEC filing |
| Mar 7, 2018 | Initial | $55,499,974 | No comparison | 14 | SEC filing |
| Mar 7, 2018 | Initial | $1,005,358 | No comparison | 1 | SEC filing |
| Mar 1, 2017 | Initial | $22,999,995 | No comparison | 10 | SEC filing |
| May 11, 2016 | Initial | $3,000,000 | No comparison | 2 | SEC filing |
| May 11, 2016 | Initial | $6,035,341 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-483102
The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.
Source: Form D, filed Jun 1, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dianna L. De Vore | Executive |
| Justin Ferber | Executive |
| Jason T. Gammack | Executive |
| Andrew D. Garst | Promoter |
| Ryan T. Gill | Promoter |
| Michael Graige | Executive |
| Kristala L. Jones Prather | Director |
| Sri Kosaraju | Director, Executive |
| Tanya Lipscomb | Promoter |
| Ron Mc Grath | Executive |
| Eric Moessinger | Director |
| Kevin D. Ness | Director, Executive |
| Bryan Roberts | Director |
| John R. Stuelpnagel | Director |
| Roger Wyse | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5720 Stoneridge Drive
Pleasanton, CA, 94588
Pleasanton, CA, 94588